Ai întrebări despre autism, ADHD, anxietate sau depresie? Găsești ghiduri clare, verificate de specialiști. Acum, acces gratuit.
This study of 1542 MS patients and 700 controls found that people with MS have lower odds of seasonal allergies compared to unaffected controls, with variations by MS disease course. Genetic analysis revealed that MS-specific genetic risk factors (HLA-DRB1*15:01 and non-MHC genetic risk scores) are associated with differential susceptibility to allergic conditions in MS patients.
A 40-year-old woman with Crohn's disease on adalimumab presented with acute transverse myelitis characterized by leg weakness and sensory loss. MRI and CSF analysis confirmed CNS demyelination, and combined with a retrospectively identified prior relapse, she was diagnosed with relapsing-remitting MS; discontinuation of adalimumab and corticosteroid treatment led to neurological improvement.
This commentary discusses a UK study of 364 multiple sclerosis patients treated with autologous hematopoietic stem cell transplantation (aHSCT), showing positive responses across all MS types, with particularly high response rates in relapsing-remitting forms. The authors argue that aHSCT represents a powerful, effective, and safer therapeutic option for MS patients compared to conventional disease-modifying treatments.
A prospective study of 61 MS patients found that four months of fingolimod treatment did not produce significant changes in anxiety or depression scores compared to baseline. At baseline, MS relapses and prior medication use were associated with depression, while recent adverse life events correlated with anxiety.
This Cochrane systematic review evaluates natalizumab, a monoclonal antibody approved for highly active relapsing-remitting MS, by synthesizing randomized controlled trials comparing its effectiveness alone or combined with other treatments versus controls or other disease-modifying therapies. The review assesses outcomes including relapse rates, disability progression, adverse events, MRI lesion activity, quality of life, and treatment discontinuation through meta-analysis.